Asensus Surgical (TRXDW) 8-K Any statements contained in this presentation that do not describe historical facts, including

Analyst Investor Event

SAGES Conference

Nashville, TN

April 17, 2015

Webcast

at:

http://ir.transenterix.com/events.cfm

Exhibit 99.1

Forward Looking Statement

2

Any statements contained in this presentation that do not describe historical facts, including

statements

about

the

beliefs

and

expectations

of

TransEnterix,

Inc.

(“TransEnterix,”

"we"

or

"our")

and other statements regarding our future plans and goals, may constitute forward-looking

statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the

Securities Exchange Act of 1934, and are intended to qualify for

the safe harbor from liability

established by the Private Securities Litigation Reform Act of 1995.

These forward-looking

statements can be identified by terminology such as "will," "expect," "anticipate," "future," "intend,"

"plan," "believe," "estimate," "confident" and similar statements. Any forward-looking statements

contained herein are based on current expectations, but are subject to a number of risks and

uncertainties that may cause actual results to differ materially

from expectations.

Such statements

are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and

which may cause results to differ materially from expectations. Factors that could cause our results

to differ materially from those described include, but are not limited to, whether the SurgiBot

system's 510(k) application(s) will be will be submitted by mid-2015 or cleared by the U.S. FDA, the

pace of adoption of our products by surgeons, the success and market opportunity of our products,

most notably the SurgiBot system, the effect on our business of existing and new regulatory

requirements, and other economic and competitive factors. For a discussion of the most significant

risks and uncertainties associated with TransEnterix's business,

please review our filings with the

Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the

year ended December 31, 2014 filed with the SEC on February 20, 2015, and other filings we make

with the SEC. You are cautioned not to place undue reliance on these forward looking statements,

which are based on our expectations as of the date of this presentation and speak only as of the

date of this presentation. We undertake no obligation to publicly update or revise any forward-

looking statement, whether as a result of new information, future events or otherwise.

2

•

Corporate Update

–

Todd M. Pope, CEO TransEnterix

•

Surgeon Speakers

–

Dr. Helmuth Billy, Ventura, CA

–

Dr. Raymond Leveillee, Miami, FL

–

Dr. Juan-Carlos Verdeja, Miami, FL

•

Q&A

•

SurgiBot System Demo

Agenda

3

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

Powered and Robotically-enabled

Next-generation Platform

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

SurgiBot

TM

Investment Highlights

5

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

Surgical robotics

Focus

•

Developing patient-side robotic platform: SurgiBot

Technology

•

Addresses unmet needs in today’s robotic offerings

•

Cost effective

•

Broad procedure applicability

Solution

•

Large addressable market –

~2M US procedures

Market

•

Strong management team

Experience

6

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

Improved surgeon

ergonomics

Benefits of

Surgical

Robotics

Advanced

visualization

Improved

dissection and

retraction strength

Enhanced precision

and control

Benefits of Surgical Robotics

SurgiBot

First Patient-side Robotic Platform

7

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

Surgeon scrubbed-in

Easily repositioned for multi-

quadrant surgery

Flexible, articulating channels &

instruments

Steerable 3DHD

Small, mobile platform

Cost effective platform

8

3DHD

Optics/Cart

SurgiBot

First Patient

-side Robotic Platform

SurgiBot

System

9

Bariatric Surgery

Cholecystectomy

Colorectal

Gynecology/Urology

Targeted US

Procedures

160K

1,140K

363K

230K

Source: Millennium Research Group US Markets Laparoscopic Devices 2014

~2M US

Laparoscopic

Procedures

Procedure Market Opportunity

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

Hospital Market Opportunity

10

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

•

•

Hospitals without

Robotic Capability

Hospitals with

Robotic Capability

•

•

•

•

•

Current robotic offerings

are not cost effective

Surgery centers –

untapped market for

robotics

Losing market share to

robotic facilities

Large underpenetrated

OUS opportunity

System price

Limited procedure volume

Invested in the strategic

and competitive value of

robotic surgery

ROI expectations

changing/under pressure

Potential for

diversification of robotic

solutions

Procedures

Price

Facilities

•

•

•

•

Significant Base of Underserved Hospitals

11

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

Mid/Small

Hospitals

•

>3,000 w/ <300

beds

•

>80% lack robotic

offering

•

Losing market share

to robotic facilities

•

Represent

>800K

target annual

procedures

Surgery Centers

•

~5,000 in US

•

Economics driving

rapid procedure

growth

•

SurgiBot System will

offer versatility and

cost benefits

Surgical Robotics

>$2B Revenue

High Growth

Combining Advanced Technology AND

Maximizing Value

Price

12

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

Traditional

Laparoscopy

>$10B Revenue

Low Growth

•

510(k) pathway

•

Successfully completed GLP

labs

•

Low-risk testing and

documentation in-process

•

510(k) Submission on track

for mid-2015

Regulatory Update

13

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

–

Helmuth Billy, MD, Ventura, CA

–

Raymond Leveillee, MD FRCS-G, Miami, FL

–

Juan-Carlos Verdeja, MD FACS, Miami, FL

Surgeon Speakers

14

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

Helmuth Billy, MD

Ventura, CA

15

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

General & Bariatric Surgeon

•

Laparoscopic training at Cedars-

Sinai, USC

•

Private Practice

•

Ventura and Oxnard, CA

•

Primarily operate at St. John’s

Regional and Community Memorial

•

Operate at freestanding outpatient

surgery center

•

Visiting Consultant Surgeon,

Hamad Hospital, Doha, Qatar

2012-present

Helmuth Billy, MD

Experience & Background

16

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

21 years laparoscopic experience

•

Routine laparoscopic procedures are:

–

Cholecystectomy

–

Gastric Sleeve

–

Gastric Bypass

–

Colons

–

Hernia repair

–

Appendectomy

•

Robotic Experience:

–

Trained, but not currently using

Helmuth Billy, MD

MIS Practice

17

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

Efficient to set up and dock, keeps room turnover time low

Ease of use amongst multiple ORs within a day

Quick

learning

curve…

second

case

was

total

OR

time

of

38

minutes

Preserves multiport lap skills already learned

Eliminates need for almost any assistance

Helmuth Billy, MD

SurgiBot System Assessment

18

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

OR Efficiency

•

Application for broad range of general surgery procedures

•

Reducing number of incisions is attractive to patients

•

May consolidate significant volume to facility that acquires

Helmuth Billy, MD

How SurgiBot System Fits My Practice

19

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

Raymond Leveillee, MD FRCS-G

Miami, FL

20

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

Urologist

•

Trained at UMASS Medical,

Brown University

•

MIS Fellowship U of Minnesota

•

Dept appointments in Urology,

Radiology, and Biomedical

Engineering

•

Academic Medical Center

•

University of Miami, 20+ years

•

Past President Southeast

Section of AUA

•

Alt. Rep, AUA BOD

Raymond Leveillee, MD FRCS-G

Experience & Background

21

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

26 years laparoscopic experience

•

Routine laparoscopic procedures are:

–

Nephrectomies

–

Prostatectomies

–

Pyeloplasties

–

Adrenalectomy

–

Reconstruction

•

Laparoscopic and Robotic Fellowship Director 99-14

•

Robotic Experience:

–

14 years, over 1,000 cases

Raymond Leveillee, MD FRCS-G

MIS Practice

22

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

Value in robotic system that keeps surgeon in

sterile field

•

Lower cost system for smaller hospitals and for

benign and some malignant conditions

•

Overcomes limitations of single port surgery

•

Adjustable triangulation

•

Clutching is a major benefit in improving

ergonomics of single port lap surgery

•

A hybrid…

combines lap experience with robotic

assistance

Raymond Leveillee, MD FRCS-G

SurgiBot System Assessment

23

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

Being in sterile field for key maneuvers

•

Value in multiple Urologic surgeries

•

Replicates lap approach that many urologists still prefer for

renal procedures

•

Urologists eager for robotic alternatives

Raymond Leveillee, MD FRCS-G

How SurgiBot System Fits My Practice

24

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

Juan-Carlos Verdeja, MD FACS

Miami, FL

25

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

General Surgeon

•

Trained at U of Miami

•

Authored first report in world's

literature on Laparoscopic Colon

Surgery

•

Primarily operate at three hospitals

in Baptist Health South Florida

•

Director of General Surgery

Division of Baptist Health Medical

Group

•

Director of Minimally Invasive

Surgery, Associate Professor and

Affiliate Dean at FIU College of

Medicine

Juan-Carlos Verdeja, MD FACS

Experience and Background

26

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

25 years laparoscopic experience, >10K cases

•

Routine laparoscopic procedures are:

–

Cholecystectomy

–

Colectomy

–

Appendectomy

–

Hernia Repair

•

Robotic Experience:

–

Nissen Fundoplication

–

Splenectomy

–

Gastrectomy

Juan-Carlos Verdeja, MD FACS

MIS Practice

27

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

3DHD is vital and significant benefit

•

Being in sterile field is important

•

Strength of flexible instruments is outstanding

•

Maintains the best approach for single site surgery with

excellent triangulation

•

Laparoscopic motion is natural after >10K cases

Juan-Carlos Verdeja, MD FACS

SurgiBot System Assessment

28

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.

•

Can be the primary tool for single port cholecystectomy

•

Extends approach to other procedures with additional vision

and strength

•

Opportunity at smaller hospitals and surgery centers in

Baptist Health Network

Juan-Carlos Verdeja, MD FACS

How SurgiBot System Fits My Practice

29

The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory

authorities for sale outside the United States.